Replacement therapy in Addison's disease

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 12, 2003, Pages 2145-2149

  Løvås, Kristian ^a   Husebye, Eystein ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Addison's disease; Adrenal failure; Dehydroepiandrosterone; Glucocorticoid; Mineralocorticoid; Replacement therapy

Indexed keywords

ALDOSTERONE; ANDROGEN; ANDROSTENEDIONE; CORTISONE ACETATE; DEOXYCORTICOSTERONE; DEXAMETHASONE; FLUDROCORTISONE; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN; HYDROCORTISONE; LIVER ENZYME; MINERALOCORTICOID; PRASTERONE; PRASTERONE SULFATE; PREDNISOLONE;

ABDOMINAL PAIN; ADDISON DISEASE; ADRENAL CORTEX DISEASE; ADRENAL INSUFFICIENCY; ADULT; AGED; AUTOIMMUNE DISEASE; BONE METABOLISM; CIRCADIAN RHYTHM; CLINICAL FEATURE; CLINICAL TRIAL; CUSHINGOID SYNDROME; DEPLETION; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; EDITORIAL; FATIGUE; FEMALE; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPERCORTISOLISM; HYPERPIGMENTATION; HYPOALDOSTERONISM; MALE; MENTAL DISEASE; MUSCLE WEAKNESS; MYALGIA; NONHUMAN; SEX DIFFERENCE; SIDE EFFECT; STANDARD; STRESS; SUBSTITUTION THERAPY; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 0346366730     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.12.2145     Document Type: Editorial

References (42)

1. OELKERS W: Adrenal insufficiency. N. Engl. J. Med. (1996) 335:1206-1212.
2. ARLT W, ALLOLIO B: Adrenal insufficiency. Lancet (2003) 361:1881-1893.
3. LABRIE F, LUU-THE V, LABRIE C et al.: Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr. Rev. (2003) 24:152-182.
4. LØVÅS K, HUSEBYE ES: High prevalence and increasing incidence of Addison's disease in western Norway. Clin. Endocrinol. (Oxf) (2002) 56:787-791.
5. WINQVIST O, KARLSSON FA, KÄMPE O: 21-Hydroxylase, a major autoantigen m idiopathic Addison's disease. Lancet (1992) 339:1559-1562.
6. TEN S, NEW M, MACLAREN N: Clinical review 130: Addison's disease 2001. J. Clin. Endocrinol. Metab. (2001) 86:2909-2922.
7. RIEDEL M, WIESE A, SCHURMEYER TH, BRABANT G: Quality of life in patients with Addison's disease: effects of different cortisol replacement modes. Exp. Clin. Endocrinol (1993) 101:106-111.
8. ARLT W, CALLIES F, VAN VLIJMEN JC et al.: Dehydroepiandrosterone replacement in women with adrenal insufficiency. N. Engl. J. Med. (1999) 341:1013-1020.
9. HUNT PJ, GURNELL EM, HUPPERT FA et al.: Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J. Clin. Endocrinol. Metab. (2000) 85:4650-4656.
10. JOHANNSSON G, BURMAN P, WIREN L et al.: Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J. Clin. Endocrinol. Metab. (2002) 87:2046-2052.
11. LØVÅS K, LOGE JH, HUSEBYE ES: Subjective health status in Norwegian patients with Addison's disease. Clin. Endocrinol. (Oxf) (2002) 56:581-588.
12. LØVÅS K, GEBRE-MEDHIN G, TROVIK TS et al.: Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. J. Clin. Endocrinol. Metab. (2003) 88:1112-1118.
13. WICHERS M, SPRINGER W, BIDLINGMAIER F, KLINGMULLER D: The influence of hydrocortisone substitution on the quality of life and parameters of bone metabolism in patients with secondary hypocortisolism. Clin. Endocrinol. (Oxf) (1999) 50:759-765.
14. AL-SHOUMER KA, BESHYAH SA, NITHTHYANANTHAN R, JOHNSTON DG: Effect of glucocorticoid replacement therapy on glucose tolerance and intermediary metabolites in hypopituitary adults. Clin. Endocrinol. (Oxf) (1995) 42:85-90.
15. DEVOGELAER JP, CRABBE J, NAGANT DE DEUXCHAISNES C: Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass. Br. Med. J. (1987) 294:798-800.
16. ZELISSEN PM, CROUGHS RJ, VAN RIJK PP, RAYMAKERS JA: Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann. Intern. Med. (1994) 120:207-210.
17. FLORKOWSKI CM, HOLMES SJ, ELLIOT JR, DONALD RA, ESPINER EA: Bone mineral density is reduced in female but not male subjects with Addison's disease. NZ Med. J. (1994) 107:52-53.
18. VALERO MA, LEON M, RUIZ VALDEPENAS MP et al.: Bone density and turnover in Addison's disease: effect of glucocorticoid treatment. Bone Miner. (1994) 26:9-17.
19. BRAATVEDT GD, JOYCE M, EVANS M, CLEARWATER J, REID IR: Bone mineral density in patients with treated Addison's disease. Osteoporos. Int. (1999) 10:435-440.
20. JODAR E, VALDEPENAS MP, MARTINEZ G, JARA A, HAWKINS F: Long-term follow-up of bone mineral density in Addison's disease. Clin. Endocrinol. (Oxf) (2003) 58:617-620.
21. ESTEBAN NV, LOUGHLIN T, YERGEY AL et al.: Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J. Clin. Endocrinol. Metab. (1991) 72:39-45.
22. KERRIGAN JR, VELDHUIS JD, LEYO SA, IRANMANESH A, ROGOL AD: Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J. Clin. Endocrinol. Metab. (1993) 76:1505-1510.
23. KRAAN GP, DULLAART RP, PRATT JJ et al.: The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different. J. Clin. Endocrinol. Metab. (1998) 83:1247-1252.
24. JEFFCOATE W: Assessment of corticosteroid replacement therapy in adults with adrenal insufficiency. Ann. Clin. Biochem. (1999) 36:151-157.
25. SCOTT RS, DONALD RA, ESPINER EA: Plasma ACTH and cortisol profiles in Addisonian patients receiving conventional substitution therapy. Clin. Endocrinol. (Oxf) (1978) 9:571-576.
26. FEEK CM, RATCLIFFE JG, SETH J et al.: Patterns of plasma cortisol and ACTH concentrations in patients with Addison's disease treated with conventional corticosteroid replacement. Clin. Endocrinol. (Oxf) (1981) 14:451-458.
27. HOWLETT TA: An assessment of optimal hydrocortisone replacement therapy [see comments]. Clin. Endocrinol. (Oxf) (1997) 46:263-268.
28. PEACEY SR, GUO CY, ROBINSON AM et al.: Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin. Endocrinol. (Oxf) (1997) 46:255-261.
29. ORTH DN, KOVACS WJ: The adrenal cortex. In: Williams textbook of endocrinology. Williams RH, Foster DW, Kronenberg HM et al. (Eds), WB Saunders, Philadelphia, PA, USA (1998):517-664.
30. DIEDERICH S, EIGENDORFF E, BURKHARDT P et al.: 11beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J. Clin. Endocrinol. Metab. (2002) 87:5695-5701.
31. ALLOLIO B, ARLT W: DHEA treatment: myth or reality? Trends Endocrinol. Metab. (2002) 13:288.
32. MELLON SH, GRIFFIN LD: Neurosteroids: biochemistry and clinical significance. Trends Endocrinol. Metab. (2002) 13:35-43.
33. MORALES AJ, NOLAN JJ, NELSON JC, YEN SS: Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J. Clin. Endocrinol. Metab. (1994) 78:1360-1367.
34. BAULIEU EE, THOMAS G, LEGRAIN S et al.: Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc. Natl. Acad. Sci. USA (2000) 97:4279-4284.
35. BARNHART KT, FREEMAN E, GRISSO JA et al.: The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J. Clin. Endocrinol. Metab. (1999) 84:3896-3902.
36. ARLT W, CALLIES F, KOEHLER I et al.: Dehydroepiandrosterone supplementanion in healthy men with an age-related decline of dehydroepiandrosterone secretion. J. Clin. Endocrinol. Metab. (2001) 86:4686-4692.
37. VAN NIEKERK JK, HUPPERT FA, HERBERT J: Salivary cortisol and DHEA: association with measures of cognition and well-being in normal older men, and effects of three months of DHEA supplementation. Psychoneuroendocrinology (2001) 26:591-612.
38. FLYNN MA, WEAVER-OSTERHOLTZ D, SHARPE-TIMMS KL et al.: Dehydroepiandrosterone replacement in aging humans. J. Clin. Endocrinol. Merab. (1999) 84:1527-1533.
39. HUPPERT EA, VAN NIEKERK JK: Dehydroepiandrosterone (DHEA) supplementation for cognitive function. Cochrane Database Syst. Rev. (2001) 2:CD000304.
40. SHIFREN JL, BRAUNSTEIN GD, SIMON JA et al.: Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N. Engl. J. Med. (2000) 343:682-688.
41. WU FCW, ECKARDSTEIN A: Androgens and coronary artery disease. Endocr. Rev. (2003) 24:183-217.
42. WOODS JR, WILLIAMS JG, TAVEL M: The two-period crossover design in medical research. Ann. Intern. Med. (1989) 110:560-566.